Development and Validation of a Nomogram For Predicting Drug-Induced Acute Kidney Injury in Hospitalized Patients

Chengxuan Yu

Graduate School, Chinese PLA General Hospital; Pharmacy Department, Medical Security Center, Chinese PLA General Hospital <https://orcid.org/0000-0002-8710-8481>

Chong Yao

Pharmacy Department, Medical Security Center, Chinese PLA General Hospital

Yu Zhu

Graduate School, Chinese PLA General Hospital; Pharmacy Department, Medical Security Center, Chinese PLA General Hospital

Siyuan Liu

Graduate School, Chinese PLA General Hospital; Pharmacy Department, Medical Security Center, Chinese PLA General Hospital

Xianghao Kong

Pharmacy Department, Medical Security Center, Chinese PLA General Hospital; College of Pharmacy, Chongqing Medical University

Daihong Guo (✉ guodh301@126.com)

Pharmacy Department, Medical Security Center, Chinese PLA General Hospital

Research

Keywords: drug-induced acute kidney injury, active surveillance, informatization, nomogram, predictive model

Posted Date: February 1st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-154354/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Drug-induced acute kidney injury (D-AKI) is associated with increased mortality and longer hospital stays. This study aims to establish a nomogram to predict the occurrence of D-AKI in hospitalized patients in a multi-drug environment.

Methods: A retrospective study among adult hospitalized patients was conducted from July 2019 to September 2019 based on the Adverse Drug Events Active Surveillance and Assessment System-2 developed by our hospital. According to the propensity score matching algorithm, four controls per case were matched to eliminate the confounding bias caused by individual baseline variables. The predictors for D-AKI were obtained by logistic regression equation and used to establish the nomogram.

Results: Among 51,772 hospitalized patients, 332 were diagnosed with D-AKI. After matching, 288 pairs and 1,440 patients were included in the study, including 1,005 cases in the development group and 435 cases in the validation group. The top three drugs in terms of incidence were amphotericin B liposome (4/52, 7.69%), amphotericin B (2/39, 5.13%) and ceftazidime (2/52, 3.85%). Six variables were independent predictors for D-AKI: alcohol abuse, the concurrent use of nonsteroidal anti-inflammatory drugs or diuretics, chronic kidney disease, lower baseline red blood cell count and neutrophil count $\geq 7 \times 10^9/L$. The area under the curve (AUC) of the prediction model in the development group and validation group were 0.787 (95%CI, 0.752 ~ 0.823) and 0.788 (95%CI, 0.736 ~ 0.840), respectively. The GiViTI calibration belts showed that the model had a good prediction accuracy for the occurrence of D-AKI ($P > 0.05$).

Conclusions: This nomogram can help identify patients at high risk of D-AKI, which was useful in preventing the progression of D-AKI and treating it in the early stages.

Background

Acute kidney injury (AKI) is one of the most serious complications of hospitalized patients, and is associated with increased risk of death and higher costs^[1, 2]. Drugs have become the third to fifth leading cause of AKI in hospitalized patients^[3]. Drug-induced acute kidney injury (D-AKI) is defined as kidney injury caused by drugs or their metabolites within 7 days after the use of one or more drugs^[4]. D-AKI is increasingly recognized as a relatively common adverse drug reaction (ADR) in clinical practice. In the United States, 18%-27% of hospital-acquired AKI cases are caused by drugs^[5, 6]. In China, the proportion of D-AKI in all AKI cases has risen from 26.5–42.9% in recent years^[7, 8]. A national multi-center AKI survey study has shown that 71.6% of AKI patients in Chinese hospitalized patients had a history of potential nephrotoxic drug use before or during kidney injury^[9].

Prevention is the key to avoiding the heavy burden of mortality and morbidity caused by AKI^[10]. Therefore, early detection of patients at risk of D-AKI will help to use medical resources more effectively, formulate D-AKI prevention strategies, and improve patient safety. Although the increase in serum creatinine (Scr) is the cornerstone of the diagnosis of AKI, its early recognition is hindered by many factors and is less accurate and timely^[11]. AKI biomarkers, such as cystatin C and neutrophil gelatinase-associated lipocalin, may improve risk assessment^[12], but these tests are expensive and far away from extensive clinical applications. Thus, it is particularly important to develop a clinically convenient, accurate and efficient D-AKI risk prediction model.

Currently, nomograms are widely used to predict D-AKI because of their intuitiveness and easy-to-understand character. However, the construction of D-AKI risk prediction models in recent studies were mostly based on specific patients^[13–15]. Nomograms are rarely used to predict the risk of D-AKI in the general hospital population in a multi-drug environment.

Therefore, based on the Adverse Drug Events Active Surveillance and Assessment System-2 (ADE-ASAS-2) developed by our hospital, we carried out a case-control study with propensity score matching to explore the clinical characteristics of patients with D-AKI and constructed a nomogram to predict the risk of D-AKI in hospitalized patients.

Materials And Methods

Study design and patient selection

This single-center, retrospective, propensity score matched case-control study was performed in a group of hospitalized patients over the age of 18. Eligible patients included those who developed AKI after treatment with nephrotoxic drugs in our hospital from June 30, 2019 to September 30, 2019.

All patient data including medical records and examination information were obtained from the Hospital Information System (HIS). The ADE-ASAS-2 was based on trigger technology and text recognition technology, which can be connected to the HIS to extract patient information. Detailed descriptions of the ADE-ASAS-2 and its applications have been described in our previous study^[16, 17]. Once the monitoring indicators trigger the inclusion criteria, the system could preliminarily determine whether a patient has developed AKI and indicate early warning signals. Since the monitoring plan was carried out in the full prescription mode, and without setting up monitoring drugs, drugs with a temporal relationship to SCr elevation could be captured as D-AKI early warning signals. An alarm case may include multiple early warning signals. Then, two clinical pharmacists conducted back-to-back evaluations to confirm the alarm results, and cases with inconsistent assessment results were referred to an expert for final judgment to determine whether D-AKI had occurred.

We defined AKI on the basis of SCr definition criteria of 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Acute Kidney Injury^[18], the inclusion criteria were as follows: 1) age $\geq$ 18 years old; 2) a full prescription model (temporary prescriptions and long-term prescriptions); 3) an increase in SCr by at least 0.3 mg/dl within 48 hours or an increase in SCr to at least 1.5 times higher than baseline within the prior 7 days. Patients with baseline SCr $>$ 5 mg/dl or no baseline SCr data were automatically excluded (n = 3824). The other exclusion criteria were as follows: 1) patients with stage 5 chronic kidney disease (CKD) (n = 61); 2) patients with absent laboratory indexes before or after medication administration (n = 97); 3) patients undergoing dialysis or who underwent nephrectomy or kidney transplantation (n = 38); 4) patients with incomplete clinical records (n = 133). The Naranjo Adverse Drug Reaction Probability Scale (Naranjo Scale) was used as a causality assessment tool^[19]. The ADR was assigned to a probability category from the total score as follows: definite $\geq$ 9, probable 5 to 8, possible 1 to 4, and doubtful $\leq$ 0. Patients with scores $\geq$ 1 were defined as D-AKI.

Controls were defined as patients treated with similar nephrotoxic drugs who did not develop AKI. To minimize confounding bias due to demographic characteristics, length of hospital stays, and duration of suspected drug

exposure, we performed a 1:4 propensity core matching between the D-AKI and non-D-AKI groups to make the groups more comparable. This study was approved by the Ethics Committee of our hospital. All patient data were kept strictly confidential.

Data collection and definitions

Patient data were monitored and extracted from the HIS through the ADE-ASAS-2. We collected the following variables. Patient characteristics included age, gender, body mass index (BMI), smoking history, alcohol abuse, hospital stay, suspected drug duration and surgical history. Comorbidities included diabetes mellitus (DM) (defined as at least 2 fasting blood glucose measurements > 7 mmol/L or use of antidiabetic agents), hypertension (defined as previous diagnosis of hypertension, previous use of antihypertensive medications, or at least 2 separate measurements of systolic pressure > 140 mmHg and/or a diastolic pressure > 90 mmHg during hospitalization), cardiovascular disease (including diagnoses of congestive heart failure, myocardial infarction, unstable angina pectoris, etc.), anemia (defined as a baseline hemoglobin value below 130 g/L in men and 120 g/L in women) and CKD [defined as having an (estimated glomerular filtration rate) eGFR < 60 mL/min/1.73 m² for 3 months with or without kidney damage or CKD explicitly mentioned in the admission diagnosis]. Concomitant use of drugs included angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics and vancomycin. Laboratory data included SCr, uric acid (UA), hemoglobin (HB), red blood cell (RBC) count, white blood cell (WBC) count, platelet (PLT) count. Secondary data, such as the eGFR, were calculated as needed. We used the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (CKD-EPI) to calculate eGFR, because it is more accurate than the Modification of Diet in Renal Disease (MDRD) formula, as recommended by clinical practice guidelines^[18, 20]. The SCr baseline was defined as the last laboratory measurement between 7 days before and 2 hours after the suspected drug administration. Other laboratory values were collected at the time of the most recent laboratory measurement prior to suspected drug administration.

Statistical analysis

SPSS statistical software (version 25.0, SPSS, IBM Corporation, USA), STATA software (version 16.0, Stata Corporation LLC, USA) and R software (version 4.0.3, the R Core Team; USA) were used to perform the statistical analysis and model development. For baseline characteristics, All data did not conform to a normal distribution, so quantitative data were expressed as median and interquartile range (IQR) and compared by Mann-Whitney U test. Qualitative data were expressed as numbers and percentages and compared by the χ^2 test or Fisher's exact test.

To make baseline characteristics similar between groups, the propensity core matching method was used to match D-AKI patients and non-D-AKI patients using the same suspected drugs. Matching with a ratio of 1:4 was performed (caliper value is 0.05) using the "psmatch2 package" of STATA software. Propensity scores were estimated by age, gender, BMI, hospital stay and suspected drug duration.

To identify the independent predictors for D-AKI, binary logistic regression analysis was used. Variables that differed significantly in univariate analysis were included in a multivariate logistic regression model ($P < 0.05$ was used for entry, and $P > 0.10$ for removal) using the Forward: LR mode. Estimates of odds ratios (ORs) and 95% confidence intervals (CIs) for predictors were computed. A nomogram was constructed according to the results of multivariable logistic regression using the "rms package" in R software. Referring to the grouping

ratios in previous studies^[15, 21], the ratio of the development and validation groups was divided into 7:3 in this study.

The discrimination of the model was evaluated by the receiver operating characteristic (ROC) curves constructed by the “pROC package” in R software, and area under the curve (AUC) was calculated. The calibration of the model was evaluated by the GiViTI calibration belts, which were implemented by the "givitIR package" in R software. In the GiViTI calibration test, the prediction model was considered poorly calibrated when $P < 0.05$; conversely, when $P > 0.05$, it was not sufficient to demonstrate a lack of model fit. A value of $P < 0.05$ was considered significant. All the reported P -values were 2-sided.

Results

Clinical characteristics of the patients

Of the patients admitted from June 30, 2019 to September 30, 2019, a total of 51,772 were monitored by ADE-ASAS-2, 3,290 (6.35%) were automatically excluded by ADE-ASAS-2, and 1,270 (2.45 %) were indicated warning signals. Among these patients, 329 (25.91%) were excluded according to our exclusion criteria. After independent evaluation by two clinical pharmacists using the Naranjo Scale to exclude 609 patients with no causal relationship to the drug, we finally identified that 332 (26.14%) patients were diagnosed with D-AKI. The overall incidence of D-AKI in hospitalized Chinese patients (aged ≥ 18) was 0.64%. Among the hospitalized patients during the study period, 23,345 patients used the same suspected drugs but did not develop D-AKI. After propensity score matching, 288 cases and 1,152 controls were finally paired. The selection process is summarized in Fig. 1. Baseline demographic and clinical characteristics before and after matching are described in Table 1. After matching, there was no significant difference between groups for each matching variable ($p > 0.05$). A total of 66 drugs were administered in the 332 D-AKI cases. The top 3 drugs in terms of incidence were amphotericin B liposome (4/52, 7.69%), amphotericin B (2/39, 5.13%) and ceftazidime (2/52, 3.85%), respectively. This study finally included 1,440 patients for analysis, randomized in a 7:3 ratio into the development group ($n = 1005$) and a validation group ($n = 435$). The baseline clinical characteristics of the development and validation groups are shown in Table 2.

Table 1
Baseline characteristics of patients before and after propensity score matched analysis

Variables	Before matched (n = 23677)			After matched (n = 1440)		
	D-AKI (N = 332)	No D-AKI (n = 23345)	P-value	D-AKI (n = 288)	No D-AKI (n = 1152)	P-value
Median age, years (IQR)	65(53–75)	56(44–66)	< 0.001	64(53–73)	65(54–74)	0.497
Males, n(%)	214(64.5)	12913(55.31)	0.001	186(64.6)	764(66.3)	0.578
Median BMI, kg/m ² (IQR)	23.3(20.8–26.0)	24.0(21.7–26.6)	< 0.001	23.4(21.1–26.1)	23.6(21.0–25.8)	0.950
Median hospital stay, days (IQR)	20(12–34)	9(6–14)	< 0.001	16(10–24)	15(19–24)	0.196
Median suspected drug duration ,days (IQR)	4(2–6)	3(1–6)	0.022	4(2–6)	3(1–7)	0.356

Table 2
Baseline Characteristics in the Development and Validation Groups

Variables	Development group (n = 1005)			Validation group (n = 435)		
	D-AKI (n = 201)	Non D-AKI (n = 804)	P-value	D-AKI (n = 87)	Non D-AKI (n = 348)	P-value
Demographic data						
Median age, years (IQR)	64(53–73)	65(54–74)	0.241	65(53–77)	65(52–75)	0.616
Males, n (%)	135(67.2)	541(67.3)	0.973	51(58.6)	223(64.1)	0.345
Median BMI, kg/m ² (IQR)	23.8(21.8–26.8)	24.1(21.6–26.0)	0.656	22.0(20.4–24.8)	22.2(20.2–25.1)	0.609
Smoking history, n (%)	92(45.8)	277(34.5)	0.003	28(32.2)	93(26.7)	0.309
Alcohol abuse, n (%)	80(39.8)	258(32.1)	0.038	26(29.9)	79(22.7)	0.161
Median hospital stay, days (IQR)	16(10–22)	14(8–22)	0.175	16(12–33)	17(11–28)	0.605
Median suspected drug duration, days (IQR)	3(2–6)	3(1–6)	0.212	5(2–9)	5(3–8)	0.986
Surgical history, n (%)	54(26.9)	241(30.0)	0.387	38(43.7)	86(24.7)	< 0.001
Concomitant use of drugs						
ACEIs, n (%)	10(5.0)	24(3.0)	0.163	5(5.7)	22(6.3)	0.842
ARBs, n (%)	23(11.4)	49(6.1)	0.009	21(24.1)	26(7.5)	< 0.001
NSAIDs, n (%)	85(42.3)	172(21.4)	< 0.001	31(35.6)	67(19.3)	0.001
Diuretics, n (%)	96(47.8)	120(14.9)	< 0.001	47(54.0)	54(15.5)	< 0.001
Vancomycin, n (%)	6(3.0)	35(4.4)	0.380	7(8.0)	12(3.4)	0.061
Comorbidities						
Diabetes mellitus, n (%)	46(22.9)	127(15.8)	0.017	27(31.0)	59(17.0)	0.003
Hypertension, n (%)	86(42.8)	309(38.4)	0.258	42(48.3)	131(37.6)	0.070
Cardiovascular disease, n (%)	57(28.4)	139(17.3)	< 0.001	39(44.8)	50(14.4)	< 0.001

Variables	Development group (n = 1005)			Validation group (n = 435)		
	D-AKI (n = 201)	Non D-AKI (n = 804)	P-value	D-AKI (n = 87)	Non D-AKI (n = 348)	P-value
Anemia, n (%)	40(19.9)	83(10.3)	< 0.001	51(58.6)	111(31.9)	< 0.001
CKD, n (%)	25(12.4)	37(4.6)	< 0.001	16(18.4)	28(8.0)	0.004
Laboratory measurements						
Median baseline SCr, mg/dL (IQR)	0.95(0.69–1.45)	0.83(0.68–1.01)	< 0.001	0.94(0.69–1.37)	0.82(0.66–1.01)	0.007
Median UA, mmol/L (IQR)	310.2(223.4–384.1)	282.0(215.0–354.4)	0.017	257.0(197.6–416.3)	270.8(194.9–356.3)	0.693
Median HB, g/L (IQR)	106(90–127)	120(102–135)	< 0.001	257.0(197.6–416.3)	270.75(194.90–356.28)	0.002
Median RBC count, $\times 10^{12}/L$ (IQR)	3.47(2.96–4.18)	3.93(3.43–4.44)	< 0.001	3.31(2.66–3.84)	3.67(4.52–9.69)	0.005
Median WBC count, $\times 10^9/L$ (IQR)	10.30(7.10–13.35)	7.83(5.55–10.91)	< 0.001	9.60(6.07–14.95)	6.98(4.52–9.69)	< 0.001
Median neutrophil count, $\times 10^9/L$ (IQR)	8.62(5.22–11.64)	5.59(3.38–8.97)	< 0.001	7.25(4.35–13.11)	5.01(2.86–7.64)	< 0.001
Neutrophil count $\geq 7 \times 10^9/L$ (%)	123(61.2)	307(38.2)	< 0.001	45(51.7)	104(29.9)	< 0.001
Median lymphocyte count, $\times 10^9/L$ (IQR)	0.94(0.60–1.51)	1.18(0.74–1.72)	< 0.001	0.82(0.50–1.24)	0.41(0.26–0.58)	0.013
Median PLT count, $\times 10^9/L$ (IQR)	176(121–245)	197(146–247)	0.010	141(78–198)	176(111–230)	0.011
Median baseline eGFR, ml/min/1.73 m ² (IQR)	74.88(49.54–97.04)	89.56(71.11–101.61)	< 0.001	74.66(47.00–98.00)	91.66(69.01–114.77)	0.001
Median NLR (IQR)	8.80(4.25–15.87)	4.79(2.28–10.16)	< 0.001	10.39(5.75–18.12)	4.97(2.25–11.51)	< 0.001
Median PLR (IQR)	175.62(105.28–292.38)	155.78(112.19–251.34)	0.213	166.28(91.89–302.49)	158.32(101.82–245.37)	0.520

Predictors of D-AKI

To confirm the predictors of D-AKI, univariate and multivariate logistic regression were performed. The potential predictors ($P < 0.05$ in the univariable analysis) were accepted for multivariate logistic regression. In the final regression model, the following variables were included: smoking history, alcohol abuse, ARBs, NSAIDs, diuretics, diabetes mellitus, cardiovascular disease, anemia, CKD, baseline SCr, baseline eGFR, baseline RBC count, neutrophil count $\geq 7 \times 10^9/L$ and NLR. In multivariate analysis, alcohol abuse (OR = 1.68, 95% CI: 1.17–2.41, $P = 0.005$), use of NSAIDs (OR = 2.56, 95% CI: 1.77–3.70, $P < 0.001$), use of diuretics (OR = 3.87, 95% CI: 2.67–5.62, $P < 0.001$), CKD (OR = 2.76, 95% CI: 1.51–5.04, $P = 0.001$), baseline RBC (OR = 0.61, 95% CI: 0.48–0.77, $P < 0.001$) and neutrophil count $\geq 7 \times 10^9/L$ (OR = 2.87, 95% CI: 2.02–4.09, $P < 0.001$) were independently associated with D-AKI. Table 3 shows the result of univariate and multivariate logistic regression analyses of 1,005 patients in the development group.

Table 3
Univariate and multivariate analysis of predictors for D-AKI

Variables	Univariate	Multivariate		
	Odds ratio (95% CI)	P-value	Odds ratio (95% CI)	P-value
Smoking history	1.61(1.17–2.20)	0.003		
Alcohol abuse	1.40(1.02–1.93)	0.039	1.68(1.17–2.41)	0.005
ARBs	1.99(1.18–3.35)	0.010		
NSAIDs	2.69(1.94–3.73)	< 0.001	2.56(1.77–3.70)	< 0.001
Diuretics	5.21(3.71–7.31)	< 0.001	3.87(2.67–5.62)	< 0.001
Diabetes mellitus	1.58(1.08–2.31)	0.018		
Cardiovascular disease	1.89(1.33–2.71)	< 0.001		
Anemia	2.16(1.43–3.27)	< 0.001		
CKD	2.95(1.73–5.02)	< 0.001	2.76(1.51–5.04)	0.001
Baseline SCr	1.23(1.06–1.43)	0.007		
Baseline eGFR	1.00(0.98–1.00)	< 0.001		
Baseline RBC	0.53(0.43–0.65)	< 0.001	0.61(0.48–0.77)	< 0.001
Neutrophil count $\geq 7 \times 10^9/L$	2.55(1.86–3.51)	< 0.001	2.87(2.02–4.09)	< 0.001
NLR	1.02(1.01–1.04)	< 0.001		

Development and validation of nomogram

A nomogram was constructed based on independent predictors from multivariate logistics regression analysis for the prediction of D-AKI (Fig. 2). In this nomogram, baseline RBC is a continuous variable, and other predictors are categorical variables, including neutrophil count $\geq 7 \times 10^9/L$, use of NSAIDs, use of diuretics,

alcohol abuse, and previous CKD. The nomogram has nine rows, with the first row being the point assignment of predictors and the second to seventh rows being predictors of D-AKI. The probability of AKI occurrence of D-AKI is predicted by matching the sum of the total scores (eighth row) with the scores on the total score table (ninth row).

To evaluate the model discrimination and reduce the overfitting bias, internal validation was performed in the validation group. Fig. 3 shows the receiver operating characteristic (ROC) curves in the development and validation groups. In our study, the area under the curve (AUC) was 0.787 (95% CI 0.752–0.823) for the development group and 0.788 (95% CI 0.736–0.840) for the validation group. The nomogram model also indicated good calibration according to GiViTI calibration belts. The risk of D-AKI estimated by the nomogram was in good agreement with the actual observation results of D-AKI, with *P*-values of 0.277 and 0.234 for the development and validation groups, respectively (Fig. 4).

Discussion

With the help of the ADE-ASAS-2, we retrospectively monitored a total of 51,772 patients in our hospital. 1270 patients triggered alarm signals and 332 of them were diagnosed with D-AKI. This study found that the total incidence of D-AKI in our adult inpatient population was about 0.64%. At present, there is still a lack of accurate incidence of D-AKI in all hospitalized populations. Previous reports in the literature have shown that the incidence of AKI in inpatients ranges from 0.7–77% depending on the definition and study population [22, 23], with a drug-related rate of 25% [24]. Therefore, although the incidence of D-AKI that we obtained is lower than that in general studies, it is still within a reasonable range.

Currently, AKI remains a common complication associated with high mortality and prolonged hospital stay [3, 24]. Previous studies have demonstrated that AKI can be prevented by early intervention in individual [10]. However, most of the current studies on AKI prediction models are based on specific patient populations [14, 15, 21], especially to predict the risk of contrast-related AKI during percutaneous coronary intervention (PCI) [13, 25]. Currently, there is no nomogram for predicting D-AKI risk based on the general Chinese patient population to accurately assess the risk of D-AKI in Chinese hospitalized patients in a multi-drug environment. Therefore, this research was dedicated to developing a simple and easy-to-use D-AKI prediction nomogram for adult inpatients to help clinicians to more accurately identify patients with potential D-AKI risk and take measures to prevent the occurrence of D-AKI.

The D-AKI risk prediction nomogram was developed by the development group and verified in the validation group. Previous research experience has shown that an AUC value greater than 0.7 indicates good predictive performance of the model [21, 26]. In our model, the AUC values for the development and validation groups were 0.787 (95%CI: 0.752–0.823) and 0.788 (95%CI: 0.736–0.840), respectively. The calibration of the model was verified by the GiViTI calibration belt. The *P*-values were greater than 0.05 in both the development and validation groups. The above shows that our model has a good ability to distinguish D-AKI patients from non-D-AKI patients without overestimating or underestimating the risk of occurrence.

The nomogram model predicts D-AKI in hospitalized patients based on six predictors, including baseline RBC count, neutrophil count $\geq 7 \times 10^9/L$, use of NSAIDs, use of diuretics, alcohol abuse, and previous CKD. Again,

these six selected predictors have been shown to be strongly associated with kidney damage in several studies^[3, 15, 21, 27, 28]. In addition, we found that in the initial population of this study, D-AKI patients were older than non-D-AKI patients (median 65 vs. 56 years; $P < 0.001$), and advanced age has become a major risk factor for AKI due to changes in renal structure and function in older adults, which has been confirmed and incorporated into many AKI risk models^[13, 15, 26]. In order to find more targeted D-AKI predictors, we balanced demographic data including age; length of hospitalization and duration of suspected drug exposure by propensity score matching. The predictors we finally found were routinely available in the HIS.

Our study concluded that the reduction in erythrocyte count and neutrophil count $\geq 7 \times 10^9/L$ has predictive significance for D-AKI. At present, there are few studies on the relationship between erythrocyte count and AKI, and the mechanism remains unknown. Both inflammation and oxidative stress may play a key role in the progression of AKI^[29, 30]. When inflammation occurs, iron metabolism and bone marrow function are affected and the proliferation and maturation of erythrocytes are inhibited^[29], resulting in a decrease in erythrocytes counts. In addition, neutrophil count as a marker of inflammation has been shown to provide additional information on the prognosis of AKI^[31, 32]. Therefore, the role of neutrophil count in the prediction of D-AKI should be valued clinically.

In this nomogram model, we found that the combination of non-steroidal anti-inflammatory drugs and diuretics contributed approximately 32 and 45 points to the predicted total score, respectively. Previous studies have shown that the two aforementioned drugs together with angiotensin-converting enzyme constitute a "triple whammy" theory^[31, 33, 34]. The pathological mechanism by which NSAIDs precipitate hemodynamically mediated kidney injury is the inhibition of renal prostaglandins, causing renal vasoconstriction to occur preferentially in the afferent arteries^[27, 35]. In addition, use of diuretics was found to be a risk factor for D-AKI in many studies^[17, 31, 36]. The mechanism is to stimulate the sympathetic nervous system and the renin-angiotensin system (RAS), which leads to hemodynamic changes and eventually renal perfusion deficit leading to AKI^[37]. CKD is another important predictor of D-AKI in inpatients. The relationship between CKD and AKI has been mentioned in many studies^[4, 21, 27]. Recent studies have shown that both are mutual risk factors and risk factors for cardiovascular disease^[4]. Similarly, eGFR, the main diagnostic indicator of CKD, has been used as an independent predictor by multiple AKI prediction models^[26, 38]. We also found a significant correlation between alcohol abuse and D-AKI. The latest research has pointed out that frequent and occasional binge drinking are associated with a 2.2-fold and 2.0-fold higher risk of CKD progression, respectively, compared with no alcohol consumption^[39]. Hence, clinicians should focus on the renal function of hospitalized patients with a history of chronic kidney disease or alcohol abuse.

The main strength of our study is the first analysis of D-AKI episodes in Chinese hospitalized adult patients by the self-developed ADE-ASAS-2 in a multi-drug environment. We also constructed a D-AKI risk prediction nomogram, which was well identified and calibrated. Compared with the predictors involved in other studies^[15, 27], our model was based on 6 variables that are widely used and easily accessible in clinical practice, and thus be applied in various medical environments. In addition, we found that both amphotericin B and its liposomes had a high incidence of D-AKI and that the incidence differed between dosage forms, which provides a direction for the next comparative study with a large sample.

However, there are several limitations of our study. First, this was a single-center retrospective study and sample selection bias was inevitable. For the same reason, we did not perform external verification, and the obtained results need to be verified by future prospective multi-center studies. Besides, the construction of this model was based on a case-control study with the risk of observation bias and confounding bias, which was minimized by applying the propensity score matching protocol. Furthermore, some variables that affect the predictive performance of D-AKI, such as cystatin C and interleukin 18^[40, 41], were ignored due to the high percentage of missing values. If these variables are combined, the predictive value may be improved. However, the sample size of this study was insufficient to adequately analyze additional variables, which means that prospective studies with more detailed data and studies with larger sample sizes are needed to verify or update.

Conclusions

This study provided information on the incidence of D-AKI among adult hospitalized patients and obtained six D-AKI predictors. On this basis, a nomogram was established to predict the occurrence of D-AKI in hospitalized population. This prediction model can help clinicians accurately predict the risk of D-AKI in adult hospitalized patients and identify potential risk patients early. Future studies are still needed for more extensive external validation.

Abbreviations

AKI: Acute kidney injury; D-AKI: drug-induced acute kidney injury; ADR: adverse drug reaction; Scr: serum creatinine; ADE-ASAS-2: adverse drug events active surveillance and assessment system-2; HIS: hospital information system; KDIGO: kidney disease: improving global outcomes; CKD: chronic kidney disease; BMI: body mass index; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; NSAIDs: nonsteroidal anti-inflammatory drugs; UA: uric acid; HB: hemoglobin; RBC: red blood cell; WBC: white blood cell; PLT: platelet; IQR: interquartile range; ROC: receiver operating characteristic; AUC: area under the curve.

Declarations

Acknowledgements

The authors thank contributions of clinical pharmacists and nephrologists who participated in this study.

Author Contributions

Chengxuan Yu: conception, design, data collection, analysis of data, drafting, and revision of manuscript. Daihong Guo: conception, design, interpretation of results and critical revision of manuscript. Chong Yao and Yu Zhu: analysis of data, interpretation of results. Siyuan Liu and Xianghao Kong: revision of manuscript.

Funding

This study was supported by the Key Project of Military Medical Innovation Project in 2017 (No. 17CXZ010) and "the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs" commissioned by the Chinese Association of Research Hospitals (NO. Y2021FH-YWPJ01).

Availability of data and materials

The data used to support the results of this study can be provided by the authors upon reasonable request.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Chinese PLA General Hospital. All patient data were kept strictly confidential.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflicts of interest.

Author details

¹ Graduate School, Chinese PLA General Hospital, Beijing, 100853, China. ² Pharmacy Department, Medical Security Center, Chinese PLA General Hospital, Beijing, 100853, China. ³ College of Pharmacy, Chongqing Medical University, Chongqing, 40016, China

References

1. RUIZ-CRIADO J, RAMOS-BARRON M A, FERNANDEZ-FRESNEDO G, et al. Long-Term Mortality among Hospitalized Non-ICU Patients with Acute Kidney Injury Referred to Nephrology [J]. *Nephron*. 2015;131(1):23–33.
2. SYKES L, NIPAH R, KALRA P, et al. A narrative review of the impact of interventions in acute kidney injury [J]. *J Nephrol*. 2018;31(4):523–35.
3. KANE-GILL S, GOLDSTEIN S J C C C. Drug-Induced Acute Kidney Injury: A Focus on Risk Assessment for Prevention [J]. 2015, 31(4): 675–684.
4. MEHTA R J B AWDISHUL. N. The 6R's of drug induced nephrotoxicity [J]. 2017, 18(1): 124.
5. PIERSON-MARCHANDISE M, GRAS V, MORAGNY J, et al. The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database [J]. *Br J Clin Pharmacol*. 2017;83(6):1341–9.
6. TABER SS, PASKO D A. The epidemiology of drug-induced disorders: the kidney [J]. *Exp Opin Drug Saf*. 2008;7(6):679–90.
7. XU X, NIE S, LIU Z, et al. Epidemiology and Clinical Correlates of AKI in Chinese Hospitalized Adults [J]. *Clinical journal of the American Society of Nephrology: CJASN*. 2015;10(9):1510–8.
8. CHE ML, YAN Y C, ZHANG Y, et al. [Analysis of drug-induced acute renal failure in Shanghai] [J]. *Zhonghua yi xue za zhi*. 2009;89(11):744–9.
9. YANG L, XING G, WANG L, et al. Acute kidney injury in China: a cross-sectional survey [J]. *Lancet*. 2015;386(10002):1465–71.

10. LI P, BURDMANN E, MEHTA R, et al. Acute kidney injury: global health alert [J]. 2013, 22(3): 253–258.
11. KASHANI K, LEVIN A, SCHETZ M. Contrast-associated acute kidney injury is a myth: We are not sure [J]. Intensive care medicine. 2018;44(1):110–4.
12. MARKWARDT D, STEIB HOLDTL C, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis [J]. Hepatology. 2017;66(4):1232–41.
13. MEHRAN R, AYMONG E D, NIKOLSKYE, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation [J]. J Am Coll Cardiol. 2004;44(7):1393–9.
14. PATIDAR K R, XU C, SHAMSEDEEN H, et al. Development and Validation of a Model to Predict Acute Kidney Injury in Hospitalized Patients With Cirrhosis [J]. Clinical translational gastroenterology. 2019;10(9):e00075.
15. ZHOU X, SUN Z, ZHUANG Y, et al. Development and Validation of Nomogram to Predict Acute Kidney Injury in Patients with Acute Myocardial Infarction Treated Invasively [J]. Scientific reports. 2018;8(1):9769.
16. CHEN C, JIA W, GUO D, et al. Development of a Computer-Assisted Adverse Drug Events Alarm and Assessment System for Hospital Inpatients in China [J]. Therapeutic innovation & regulatory science, 2020, 54(1): 32–41.
17. YU C, GUO D, YAO C, et al. Clinical Characteristics of Hospitalized Patients with Drug-Induced Acute Kidney Injury and Associated Risk Factors: A Case-Control Study [J]. BioMed research international, 2020, 2020: 9742754.
18. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. (2012) [J]. Kidney Int Suppl, 2012, 2: 1-138.
19. NARANJO C A, BUSTO U, SELLERS E M, et al. A method for estimating the probability of adverse drug reactions [J]. Clin Pharmacol Ther. 1981;30(2):239–45.
20. LEVEY A S, STEVENS L A, SCHMID C H, et al. A new equation to estimate glomerular filtration rate [J]. Ann Intern Med. 2009;150(9):604–12.
21. WANG Q, TANG Y, ZHOU J, et al. A prospective study of acute kidney injury in the intensive care unit: development and validation of a risk prediction model [J]. Journal of translational medicine. 2019;17(1):359.
22. JAMES M T, HEMMELGARN B R, WIEBE N, et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study [J]. Lancet. 2010;376(9758):2096–103.
23. HAN S S, AHN S Y, KIMS, et al. Duration of acute kidney injury and mortality in critically ill patients: a retrospective observational study [J]. BMC Nephrol. 2013;14:133.
24. SALES G T M, FORESTO R D. Drug-induced nephrotoxicity [J]. Revista da Associacao Medica Brasileira (1992), 2020, 66Suppl 1(Suppl 1): s82-s90.
25. HUANG C, LI S X, MAHAJANS, et al. Development and Validation of a Model for Predicting the Risk of Acute Kidney Injury Associated With Contrast Volume Levels During Percutaneous Coronary Intervention [J]. JAMA network open. 2019;2(11):e1916021.
26. BELL S, JAMES M T, FARMER C K T, et al. Development and external validation of an acute kidney injury risk score for use in the general population [J]. Clinical kidney journal. 2020;13(3):402–12.

27. GUAN C, LI C, XU L, et al. Risk factors of cardiac surgery-associated acute kidney injury: development and validation of a perioperative predictive nomogram [J]. *J Nephrol.* 2019;32(6):937–45.
28. MOTWANI SS, MCMAHON G M, HUMPHREYS B D, et al. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin [J]. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology.* 2018;36(7):682–8.
29. DESWAL A, PETERSEN N, FELDMAN A, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST) [J]. 2001, 103(16): 2055–2059.
30. SEMBA RD, PATEL K V FERRUCCIL, et al. Serum antioxidants and inflammation predict red cell distribution width in older women: the Women's Health and Aging Study I [J]. *Clinical nutrition (Edinburgh, Scotland),* 2010, 29(5): 600–604.
31. KANE-GILL S L GOLDSTEINSL. Drug-Induced Acute Kidney Injury: A Focus on Risk Assessment for Prevention [J]. *Crit Care Clin.* 2015;31(4):675–84.
32. SUN X P, LI J, ZHU W W, et al. Platelet to Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [J]. *Angiology.* 2018;69(1):71–8.
33. LOBOZ K K, SHENFIELD GM. Drug combinations and impaired renal function – the 'triple whammy' [J]. *Br J Clin Pharmacol.* 2005;59(2):239–43.
34. DREISCHULTE T, MORALES D R, BELL S, et al. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury [J]. *Kidney international.* 2015;88(2):396–403.
35. KHAN S, LOI V, ROSNER MH. Drug-Induced Kidney Injury in the Elderly [J]. *Drugs Aging.* 2017;34(10):729–41.
36. CASPI O, HABIB M, COHEN Y, et al. Acute Kidney Injury After Primary Angioplasty: Is Contrast-Induced Nephropathy the Culprit? [J]. *Journal of the American Heart Association.* 2017;6(6):e005715.
37. WANG C, PEI Y Y, MA Y H, et al. Risk factors for acute kidney injury in patients with acute myocardial infarction [J]. *Chin Med J.* 2019;132(14):1660–5.
38. HU X Y, LIU D W, QIAO Y J, et al. Development and Validation of a Nomogram Model to Predict Acute Kidney Disease After Nephrectomy in Patients with Renal Cell Carcinoma [J]. *Cancer management research.* 2020;12:11783–91.
39. JOO YS, KOH H, NAM K H, et al. Alcohol Consumption and Progression of Chronic Kidney Disease: Results From the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease [J]. *Mayo Clinic proceedings,* 2020, 95(2): 293–305.
40. MAIWALL R, KUMAR A, BHARDWAJ A, et al. Cystatin C predicts acute kidney injury and mortality in cirrhotics: A prospective cohort study [J]. *Liver international: official journal of the International Association for the Study of the Liver.* 2018;38(4):654–64.
41. CONNOLLY M, MCENEANEY D, MENOWN I, et al. Novel Biomarkers of Acute Kidney Injury After Contrast Coronary Angiography [J]. *Cardiol Rev.* 2015;23(5):240–6.

Figures

Figure 1

Flow diagram of study population enrollment

Figure 2

Nomogram for the prediction of D-AKI

Figure 3

The ROC curve in the development (A) and validation (B) groups

Figure 4

The GiViTI calibration belt in the development (A) and validation (B) groups